Scarica l'app Stockscreener
0.3117
3.50%
-0.0113
Dopo l'orario di chiusura:
.32
0.0083
+2.66%
Precedente Chiudi:
$0.323
Aprire:
$0.3256
Volume 24 ore:
515.04K
Relative Volume:
0.15
Capitalizzazione di mercato:
$4.48M
Reddito:
-
Utile/perdita netta:
$-13.24M
Rapporto P/E:
-0.0353
EPS:
-8.83
Flusso di cassa netto:
$-16.85M
1 W Prestazione:
+5.09%
1M Prestazione:
-31.30%
6M Prestazione:
-72.17%
1 anno Prestazione:
-90.41%
Intervallo 1D:
$0.29
$0.333
Intervallo di 1 settimana:
$0.23
$0.347
Portata 52W:
$0.23
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Nome
Virpax Pharmaceuticals Inc
Settore
Industria
Telefono
610-727-4597
Indirizzo
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Confronta VRPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.3117 | 4.48M | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc Borsa (VRPX) Ultime notizie
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - The Manila Times
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com India
Virpax Secures Critical $6M Funding: Game-Changing Move for Probudur Development - StockTitan
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
What's Going With Penny Stock Virpax Pharmaceuticals On Monday? - MSN
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Virpax Pharmaceuticals enacts reverse stock split By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals Regains Nasdaq Compliance - MSN
Amendments to Independent Contractor Agreements at Virpax Pharmaceuticals Clarify Roles and Responsibilities - Defense World
Virpax Updates Executive Agreements for Legal Compliance - TipRanks
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Virpax Pharmaceuticals, Inc. Appoints Jaydriane Panis to the Board - Marketscreener.com
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals names new board director By Investing.com - Investing.com UK
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals announces board member resignation By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces board member resignation - Investing.com
Virpax Pharmaceuticals Announces Board Member Resignation - TipRanks
Virpax Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com Canada
Virpax Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation - MSN
VRPX (Virpax Pharmaceuticals) Enterprise Value : $3.71 Mil (As of Dec. 01, 2024) - GuruFocus.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals lowers quorum requirement - Investing.com India
Virpax Pharmaceuticals : Amendments to Bylaws Form 8 K - Marketscreener.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Virpax Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Virpax Pharmaceuticals regains Nasdaq compliance - Investing.com India
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Virpax Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements and Makes Key Appointments - Defense World
Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations - TipRanks
Maxim Group Downgrades Virpax Pharmaceuticals (VRPX) - MSN
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur - Marketscreener.com
Why Is Virpax Pharmaceuticals Stock Gaining On Friday? - Benzinga
Virpax Pharmaceuticals extends NIH pain management research By Investing.com - Investing.com Australia
Virpax Pharma Gets Government Cooperation Deal Extension - Marketscreener.com
Virpax Pharmaceuticals extends NIH pain management research - Investing.com India
Virpax Pharmaceuticals Inc Azioni (VRPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):